港股異動 | 金斯瑞(1548.HK)升超7% 中期收益同比增37.97%
格隆匯8月24日丨金斯瑞(1548.HK)續升超7%,2日累計升幅達20%。現報37.45港元,成交額近6億港元,總市值達788億港元。金斯瑞生物科技23日公佈,該集團上半年取得收益2.296億美元,同比增加37.97%;母公司擁有人應占虧損9112.2萬美元,同比收窄19.43%。期內集團大量投入研發活動及人才招聘,兩者均是業務長期可持續增長的主要推動因素。此外,近日高瓴擬以2.75億美元入股子公司Probio Cayman(蓬勃生物)。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.